Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression

British Journal of Haematology

Volumn 166, Issue 3, 2014, Pages 455-457

  Shimada, Kazuyuki ^a   Tomita, Akihiro ^a   Saito, Shigeki ^a   Kiyoi, Hitoshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD20; Chronic lymphocytic leukaemia; Drug resistance; Ofatumumab; Rituximab

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD5 ANTIGEN; OFATUMUMAB; RITUXIMAB;

AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE EFFECTIVENESS; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOMA; MONOTHERAPY; PRIORITY JOURNAL; SPLEEN SIZE; TUMOR VOLUME;

CD20; CHRONIC LYMPHOCYTIC LEUKAEMIA; DRUG RESISTANCE; OFATUMUMAB; RITUXIMAB;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TREATMENT OUTCOME;

EID: 84904038838     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12857     Document Type: Article

References (10)

1. Beurskens, F.J., Lindorfer, M.A., Farooqui, M., Beum, P.V., Engelberts, P., Mackus, W.J., Parren, P.W., Wiestner, A. & Taylor, R.P. (2012) Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. The Journal of Immunology, 188, 3532-3541.
2. Cheson, B.D. (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Journal of Clinical Oncology, 28, 3525-3530.
3. Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., Belhadj, K., Bordessoule, D., Ferme, C. & Tilly, H. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116, 2040-2045.
4. Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A. & Introna, M. (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 98, 3383-3389.
5. Hiraga, J., Tomita, A., Sugimoto, T., Shimada, K., Ito, M., Nakamura, S., Kiyoi, H., Kinoshita, T. & Naoe, T. (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood, 113, 4885-4893.
6. Smith, M.R. (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 22, 7359-7368.
7. Teeling, J.L., French, R.R., Cragg, M.S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P.W., Hack, C.E., Dechant, M., Valerius, T., van de Winkel, J.G. & Glennie, M.J. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 104, 1793-1800.
8. Teeling, J.L., Mackus, W.J., Wiegman, L.J., van den Brakel, J.H., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W., Glennie, M.J. & van de Winkel, J.G. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. The Journal of Immunology, 177, 362-371.
9. Tokunaga, T., Tomita, A., Sugimoto, K., Shimada, K., Iriyama, C., Hirose, T., Shirahata-Adachi, M., Suzuki, Y., Mizuno, H., Kiyoi, H., Asano, N., Nakamura, S., Kinoshita, T. & Naoe, T. (2014) De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Science, 105, 35-43.
10. Wierda, W.G., Padmanabhan, S., Chan, G.W., Gupta, I.V., Lisby, S. & Osterborg, A. (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood, 118, 5126-5129.